Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Workday Inc (WDAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Workday Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.01 (market cap $39.89B), while Workday Inc trades at $140.72 (market cap $34.32B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Workday Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | WDAY | |
|---|---|---|
Market Cap | $39.89B | $34.32B |
Sector | Health | Technology |
52-Week High | $491.22 | $247.69 |
52-Week Low | $278.09 | $112.55 |
Enterprise Value | $38.15B | $33.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Workday (WDAY) trades at $138.95, up 0.44% with a bullish technical signal. The stock shows strong fundamental momentum with Q1 2026 EPS beating expectations at $2.66 versus $2.51, continuing a trend of earnings outperformance. Revenue growth remains robust, projected to reach $9.9B in 2026, while the company maintains high gross margins of 75.77%. Recent news highlights AI-driven product growth with agentic AI ACV tripling year-over-year.
The outlook remains positive with a $157.30 analyst consensus price target representing 13% upside. Key opportunities include AI adoption driving larger expansion deals, while risks involve a pending California lawsuit over AI bias allegations and elevated valuation multiples. Operating cash flow strength at $2.46B supports continued investment in growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Workday Inc
Workday is a software company that offers human capital management, or HCM, financial management, and business planning solutions. Known for being a cloud-only software provider, Workday is headquartered in Pleasanton, California. Founded in 2005, Workday now employs over 12,000 employees.
Read more on WDAY →
